Changes in cardiac magnetic resonance measurements and clinical parameters: benchmarked to changes in how a patient “feels” (emPHasis-10 (E-10), n=118), “functions” (incremental shuttle walk test (ISWT), n=146) or “survives” (1-year mortality post-follow-up, n=254)
| Improved | Stable | Worsened | ||||
| Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
| E-10 | n=42 | n=55 | n=21 | |||
| E-10 (points) | 37±10 | 21±11 | 29±12 | 29±12 | 24±10 | 37±7 |
| RVEF (%) | 32±12 | 42±13 | 34±12 | 42±10 | 38±10 | 43±8 |
| RVEDV (mL) | 208±66 | 182±59 | 200±78 | 201±74 | 174±69 | 163±57 |
| RVESV (mL) | 146±60 | 110±53 | 138±68 | 122±60 | 112±56 | 94±40 |
| ISWT | n=57 | n=64 | n=25 | |||
| Walk distance (m) | 249±181 | 409±197 | 197±1501 | 196±148 | 259±16 | 158±142 |
| RVEF (%) | 31±10 | 42±10 | 34±11 | 40±10 | 33±12 | 38±10 |
| RVEDV (mL) | 235±70 | 216±86 | 208±79 | 196±74 | 187±69 | 192±70 |
| RVESV (mL) | 164±62 | 128±62 | 144±68 | 122±61 | 129±65 | 121±55 |
| Mortality | Survivors n=229 | Non-survivors n=25 | ||||
| RVEF (%) | 34±11 | 41±11 | 31±13 | 36±16 | ||
| RVEDV (mL) | 207±71 | 195±71 | 202±79 | 207±85 | ||
| RVESV (mL) | 141±62 | 118±56 | 144±72 | 139±75 | ||
Data are presented as mean±sd, unless otherwise stated. RVEF: right ventricular ejection fraction; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume. Measurements were taken at baseline before treatment and at follow-up (12±6 months). Improvement was defined as an increase of at least 47.5 m in the ISWT, a decrease of at least 6 points in the E-10 score and 1 year survival post-follow-up, whereas worsening was defined as a reduction in the ISWT of at least 47.5 m, an increase of 6 points in the E-10 score or mortality. Otherwise, patients were described as stable.